BCL2L1 and pancreatic neoplasm: Notable studies include the use of DT2216, a Bcl‐xl‐specific degrader, which, when combined with gemcitabine, has shown to effectively overcome resistance in pancreatic cancer by promoting apoptosis more efficiently than either agent on its own.20